Bridget Stensgard

2.1k total citations
17 papers, 1.8k citations indexed

About

Bridget Stensgard is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Bridget Stensgard has authored 17 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Oncology. Recurrent topics in Bridget Stensgard's work include Heat shock proteins research (12 papers), Toxin Mechanisms and Immunotoxins (4 papers) and Protein Structure and Dynamics (3 papers). Bridget Stensgard is often cited by papers focused on Heat shock proteins research (12 papers), Toxin Mechanisms and Immunotoxins (4 papers) and Protein Structure and Dynamics (3 papers). Bridget Stensgard collaborates with scholars based in United States, France and Japan. Bridget Stensgard's co-authors include David O. Toft, W. Patrick Sullivan, Shiro Soga, Leonard Μ. Neckers, Shiro Akinaga, Theodor W. Schulte, D O Toft, David F. Smith, William J. Welch and Hiroshi Kosano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Bridget Stensgard

17 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bridget Stensgard United States	14	1.6k	366	199	174	164	17	1.8k
Janet Owens‐Grillo United States	12	1.1k 0.7×	356 1.0×	133 0.7×	115 0.7×	98 0.6×	16	1.4k
Shiro Soga Japan	16	1.0k 0.6×	202 0.6×	111 0.6×	143 0.8×	102 0.6×	26	1.2k
Martina Koeva United States	7	1.7k 1.1×	219 0.6×	140 0.7×	502 2.9×	172 1.0×	12	2.0k
Theodor W. Schulte United States	16	2.7k 1.7×	615 1.7×	314 1.6×	385 2.2×	261 1.6×	18	3.1k
Irina Krykbaeva United States	8	1.3k 0.8×	160 0.4×	127 0.6×	284 1.6×	84 0.5×	12	1.5k
Patrick Fadden United States	13	1.4k 0.9×	182 0.5×	73 0.4×	264 1.5×	69 0.4×	21	1.7k
Daniel L. Riggs United States	25	2.0k 1.2×	349 1.0×	120 0.6×	154 0.9×	44 0.3×	36	2.3k
Aurélie de Thonel France	23	1.4k 0.9×	231 0.6×	64 0.3×	340 2.0×	86 0.5×	35	1.8k
Marissa Powers United Kingdom	7	901 0.6×	180 0.5×	83 0.4×	204 1.2×	98 0.6×	14	1.0k
David R. Loiselle United States	21	927 0.6×	175 0.5×	53 0.3×	174 1.0×	39 0.2×	31	1.3k

Countries citing papers authored by Bridget Stensgard

Since Specialization

Citations

This map shows the geographic impact of Bridget Stensgard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bridget Stensgard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bridget Stensgard more than expected).

Fields of papers citing papers by Bridget Stensgard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bridget Stensgard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bridget Stensgard. The network helps show where Bridget Stensgard may publish in the future.

Co-authorship network of co-authors of Bridget Stensgard

This figure shows the co-authorship network connecting the top 25 collaborators of Bridget Stensgard. A scholar is included among the top collaborators of Bridget Stensgard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bridget Stensgard. Bridget Stensgard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

McGee‐Lawrence, Meghan E., Xiaodong Li, Hai Wu, et al.. (2013). Runx2 Protein Represses Axin2 Expression in Osteoblasts and Is Required for Craniosynostosis in Axin2-deficient Mice*. Journal of Biological Chemistry. 288(8). 5291–5302. 32 indexed citations

2.

McGee‐Lawrence, Meghan E., Angela L. McCleary‐Wheeler, Frank J. Secreto, et al.. (2011). Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone. 48(5). 1117–1126. 64 indexed citations

3.

Casper, Michelle E., Meghan E. McGee‐Lawrence, Bridget Stensgard, et al.. (2010). Histone Deacetylase 3 Depletion in Osteo/Chondroprogenitor Cells Decreases Bone Density and Increases Marrow Fat. PLoS ONE. 5(7). e11492–e11492. 96 indexed citations

4.

Hubbard, Joleen M., Charles Erlichman, David O. Toft, et al.. (2010). Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Investigational New Drugs. 29(3). 473–480. 33 indexed citations

5.

McCollum, Andrea K., Cynthia J. TenEyck, Bridget Stensgard, et al.. (2008). P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response. Cancer Research. 68(18). 7419–7427. 57 indexed citations

6.

Chadli, Ahmed, Elizabeth S. Bruinsma, Bridget Stensgard, & David O. Toft. (2008). Analysis of Hsp90 Cochaperone Interactions Reveals a Novel Mechanism for TPR Protein Recognition. Biochemistry. 47(9). 2850–2857. 20 indexed citations

7.

McCollum, Andrea K., et al.. (2007). Resistance due to the stress response surpasses the contribution of P-glycoprotein mediated resistance to HSP90-targeted therapy. 6. 1 indexed citations

8.

Arlander, Sonnet J.H., Sara J. Felts, Jill M. Wagner, et al.. (2005). Chaperoning Checkpoint Kinase 1 (Chk1), an Hsp90 Client, with Purified Chaperones. Journal of Biological Chemistry. 281(5). 2989–2998. 70 indexed citations

9.

Goetz, Matthew P., David O. Toft, Joel M. Reid, et al.. (2005). Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer. Journal of Clinical Oncology. 23(6). 1078–1087. 267 indexed citations

10.

Haluska, Paul, D O Toft, Alfred Furth, et al.. (2004). A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. Journal of Clinical Oncology. 22(14_suppl). 3058–3058. 3 indexed citations

11.

Haluska, Paul, D O Toft, Alfred Furth, et al.. (2004). A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. Journal of Clinical Oncology. 22(14_suppl). 3058–3058. 9 indexed citations

12.

Chadli, Ahmed, et al.. (2000). Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proceedings of the National Academy of Sciences. 97(23). 12524–12529. 130 indexed citations

13.

Kosano, Hiroshi, et al.. (1998). The Assembly of Progesterone Receptor-hsp90 Complexes Using Purified Proteins. Journal of Biological Chemistry. 273(49). 32973–32979. 202 indexed citations

14.

Schulte, Theodor W., Shiro Akinaga, Shiro Soga, et al.. (1998). Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress and Chaperones. 3(2). 100–100. 329 indexed citations

15.

Sullivan, W. Patrick, et al.. (1997). Nucleotides and Two Functional States of hsp90. Journal of Biological Chemistry. 272(12). 8007–8012. 210 indexed citations

16.

Johnson, Jill L., et al.. (1996). The involvement of p23, hsp90, and immunophilins in the assembly of progesterone receptor complexes. The Journal of Steroid Biochemistry and Molecular Biology. 56(1-6). 31–37. 66 indexed citations

17.

Smith, David F., Bridget Stensgard, William J. Welch, & D O Toft. (1992). Assembly of progesterone receptor with heat shock proteins and receptor activation are ATP mediated events.. Journal of Biological Chemistry. 267(2). 1350–1356. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact